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Cholesterol ester transfer protein
Apolipoprotein Fa b s t r a c t
Apolipoprotein F is a component protein mainly secreted by liver and resides on several lipoprotein clas-
ses. It can inhibit lipids transfer between different lipoproteins. FXR is a member of the nuclear receptor
superfamily which is also highly expressed in the liver. It modulates bile acids synthesis and lipids
metabolism by transcriptional regulation. We aimed to determine whether apoF can be regulated by
FXR. The FXR agonist Chenodeoxycholic acid (CDCA) and GW4064 both can activate the expression of
apoF in liver cell lines and in C57/BL6 mouse liver. This is dependent on the binding of FXR to the FXR
element ER1 (2904 to 2892 bp) in the apoF gene promoter. Taken together, we have identiﬁed apoF
as likely another target gene of FXR.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Apolipoprotein F (apoF), also known as Lipid transfer inhibitor
protein (LTIP), is an apolipoprotein mainly located in HDL [1,2]; a
small amount also has been found in LDL. It can inhibit Cholesteryl
Ester Transfer Protein (CETP) activity. In plasma, CETP mediates the
net transfer of Cholesteryl Ester (CE) from LDL and HDL to VLDL in
return for triglyceride (TG) [3,4]. This lipid transfer event is known
to reduce HDL level in plasma, thus apoF is thought to be related to
higher HDL levels in plasma due to its natural CETP inhibition func-
tion. ApoF decreases the net ﬂux of CE from HDL to VLDL. Because
there is a relatively short plasma half-life for VLDL, this exchange is
proposed to facilitate the clearance of HDL-derived CE, thus apoF
can promote reverse cholesterol transport [2]. Previous research
indeed shows that apolipoprotein F may participate in altering
the plasma TG and HDL levels via its inhibition activity on CETP.
In a study with 397 Japanese healthy and 221 hypertriglyceridemicsubjects enrolled, serum apoF concentration was correlated posi-
tively with HDL cholesterol and apo A-I levels in males but not in
females, negatively with apoB and triglyceride levels. In hypertri-
glyceridemic patients, apoF concentration in plasma was lower
than that in healthy controls [5].
Farnesoid X receptor is one of the members of the nuclear
receptor super family. It participates in the regulations of bile
acids, lipid and glucose metabolisms, with CDCA serving as its
most suitable native ligand [6]. The FXR knock-out animal model
shows a decrease in the clearance of serum HDL [7,8]. FXR activa-
tion also promotes the clearance of circulating TG [9,10]. In vivo
treatment with the FXR agonist GW4064 signiﬁcantly improves
hypercholesterolemia in both ob/ob mice and db/db mice [10].
FXR and apoF both have highly expression in the liver, and both
of them participate in the lipid metabolism and its homeostasis. So
we sought to examine if FXR plays a role in human Hepatoma cell
line HepG2with respect to the regulation of the expression of apoF.
To test this supposition, we explored the relationship between
apoF and FXR. This may contribute to the notion that FXR could
be a potential molecular target in lipid metabolism.2. Methods and materials
2.1. Animals
All experiments were approved by the Animal Ethics Board of
The Third Military Medical University on animal welfare. C57/BL6
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University) were kept under standard laboratory conditions (food
and water given ad libitum, 21 ± 2 C environment temperature
and a 12 h light/dark cycle). Male mice at 8 week were used on this
study.2.2. Cell culture
Hepatoma cell line HepG2 and fetal liver cell line L02 were pur-
chased from ATCC, cultured in DMEM or RPMI 1640 media with
10% fetal bovine serine, 100 U/ml penicillin and 0.1 mg/ml strepto-
mycin at 37 C in 5% CO2 atmosphere.2.3. RT-PCR
HepG2 or L02 cells (106) were treated with CDCA or GW4064
respectively for 24 h. Cells were starved for 2 h before the addition
of ligand, then the cells were harvested by Tripure regent and the
total RNA were extracted. The toal RNA were reverse transcript to
cDNA by M-MLV reverse transcript kit (Promega) RT-PCR were per-
formed with the Taq polymerase kit (Takara) to test the mRNA le-
vel of LTIP in human liver cell lines. Primers used in this
experiment were included in Table S1 (Supplementary Material).2.4. Real time quantitative PCR
HepG2 or L02 cell lines (about 106) were treated with CDCA in
different concentrations for 24 h. Cells were starved for 2 h before
the addition of ligand, then the total RNA were extracted and re-
verse transcript into cDNA with M-MLV reverse transcript kit (Pro-
mega). Real time quantitative PCR were performed with EvaGreen
Ssofast supermix (Bio-Rad) on IQ5 real time PCR cycler. (Bio-Rad)
to assay the mRNA level of apoF in HepG2 and L02 cells when trea-
ted with CDCA. Primers used in this experiment were included in
Table S1 (Supplementary Material).2.5. Western blotting
HepG2 or L02 cells (about 106) were treated with CDCA or
GW4064 respectively in different concentrations for 24 h. Cells
were starved for 2 h before the addition of ligand, then the cultured
cells were harvested and the total protein was extracted by RIPA
Lysis Buffer (Beyotime). Western Blotting were performed to tested
the protein level of LTIP in cultured liver cells when treated with
CDCA or GW4064, anti LTIP antibody was purchased from Santa
Cruz.2.6. Luciferase reporter assay
Through bioinformatic analysis by online nuclear binding site
search tool (www.nubiscan.unibas.ch), we have found that the 50
ﬂanking region of the apoF gene promoter may contain FXRE bind-
ing site ER1 (2904 to 2892 bp). Genomic DNA were extracted
from HepG2 cells, using PCR ampliﬁcation and plasmids recon-
struction, the (3289 to +22 bp) and (1872 to +36 bp) region of
apoF gene were reconstructed into the PGL3-basic plasmid which
contain luciferase reporter gene, acquired reconstructed plasmids
pGL3/apoF(3289 to +22 bp)and pGL3/apoF(1872 to +36 bp).
The reconstructed plasmids were co-transfected into the HepG2
cell with FXR expression plasmid vp-FXR. By Luciferase reporter
assay, the ﬂuorescence was read on a spectrophotometer (Thermo
Scientiﬁc), the activities of the different regions of the apoF
promoter were analyzed. Primers used in this experiment were
included in Table S1 (Supplementary Material).2.7. ChIP
Speciﬁc primer (sequences were included in Supplementary
Table 1) which ampliﬁed the 2955 to 2759 bp of the apoF pro-
moter region which contains the ER1 (evert repeat separated by 1
base pair) binding site were designed to performed in the ChIP as-
say. HepG2 cells (106) were treated with 100 lmol/L CDCA for 24 h.
Then the cells were washed by PBS for twice, scratched, and trans-
ferred into a new sterilized EP tube, then centrifuged to collect the
cell pallets. 200 ll SDS lysis buffer were added into the cells, cells
were then resuspended, placed on ice for 10 min, sonicated by
ultrasound using a Palmer ultrasound equipment. The genomic
DNA was sheared into 200–1000 base pairs. The ChIP assay was
performed with the ChIP kit (Millipore 17–295) following the
instruction. Anti FXR antibody (Santa-Cruz, sc-1204c) and the goat
IgG were used as treatment and control, respectively. The DNA
fragments which interact with FXR were collected, the result were
tested by PCR using the primers mentioned. Primers used in this
experiment were included in Table S1 (Supplementary Material).
2.8. Animal model experiment
C57BL/6micewere used as animalmodel, male C57BL/6 (4 weeks
old) were divided random into three groups treated with different
doze of CDCA (control, 10 mg/kg, 50 mg/kg) respectively by intragas-
tric administration for a week, the liver was separated and the total
RNA and total protein were extracted. RT-PCR and Western Blotting
were performed to test themRNAandprotein levels of the liver tissue
of C57BL/6 when treated with CDCA for 1 week. Primers used in this
experiment were included in Table S1 (Supplementary Material).3. Results
3.1. FXR agonist induces the LTIP expression in liver cell lines
We used two cell lines, HepG2 and L02 as cell model to study the
relationship between apoF and FXR. Cells were treated with CDCA
or GW4064, and then the expression of apoF was measured. Since
SHP is recognized as a typical FXR target gene and can be obviously
induced by FXR agonist, we also measured the SHP mRNA level to
monitor the activation of FXR. When treated with CDCA or GW4064
for 24 h, the SHPmRNA levels increased signiﬁcantly, indicating that
CDCA and GW4064 effectively activate FXR (Fig. S1). The apoFmRNA
andprotein levelswerealso increasedbyCDCAorGW4064 treatment
in a dose-dependent manner (Figs. 1 and 2). These results suggested
that FXR activation up-regulates apoF expression in liver cells.
3.2. The induced up-regulation of LTIP is depended on its promoter
region containing FXRE
To illustrate whether the FXR induced up-regulation of apoF is
dependent on its promoter, we have reconstructed two plasmids
on the basis of reporter plasmid pGL3. One of the reconstructed
plasmids pGL3/apoF(3289 to +22 bp) contains the full length of
the scanned promoter of humans, another reconstructed plasmids
pGL3/apoF(1872 to +36 bp) contains the truncated or proximal
human apoF promoter. The two reconstructed plasmids and FXR
expression plasmid vp-FXR were transfected into the HEK 293
cells, and the transfected cells were treated with or without CDCA
for 24 h. The ﬂuorescence was read on a spectrophotometer (Ther-
mo Scientiﬁc). In the presence of pGL3/apoF(3289 to +22 bp), the
reporter activity increased about 10 times with the presence of
vp-FXR compared with the absence of vp-FXR, while the
reconstructed plasmid pGL3/apoF(1872 to +36 bp) shows a
slight reporter activity in the presence of vp-FXR versus in the
Fig. 1. FXR agonist CDCA and GW4064up-regulate mRNA level of apoF in L02 and HepG2 cell line. L02 and HepG2 cell were treated with CDCA (0 lmol/L, 25 lmol/L, 50 lmol/
L, 100 lmol/L) and GW4064 (0 lmol/L, 0.02 lmol/L, 0.2 lmol/L, 2 lmol/L) for 24 h in a condition medium with 2% FBS. apoF mRNA level were assessed by RT-PCR. A, B: L02
and HepG2 treated with CDCA, E, F: L02 and HepG2 treated with gw4064: C, D, G, H: optic density rate of apoF and bactin; I, J: apoF mRNA level assessed by real time PCR in
L02 and HepG2 cell line after treated with CDCA at indicated concentration. ⁄: compared with control, P < 0.05.
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gest that it is the apoF promoter region(3289 to 1872 bp) that is
responsible for the FXR induced up-regulation, and support that
the predicted FXRE located in the 2904 to 2892 bp could be of
vital for the FXR binding and the sequential transcriptional
up-regulation.3.3. FXR interact with the FXRE in LTIP promoter region
Luciferse reporter assays suggested that the predicted FXRE lo-
cated in 2904 to 2892 bp bp in apoF gene promoter was highly
suspected to binding with FXR. However whether this event occurs
in cells needs further clariﬁcation. To illustrate this, ChIP (Chroma-
Fig. 2. FXR agonist CDCA and GW4064 up-regulate apoF protein level in HepG2 and L02 cell L02 and HepG2 cell were treated with CDCA (0 lmol/L, 25 lmol/L, 50 lmol/L,
100 lmol/L) and GW4064 (0 lmol/L, 0.02 lmol/L, 0.2 lmol/L, 2 lmol/L) for 24 h in a condition medium with 2% FBS. apoF mRNA level were assessed by RT-PCR. A: HepG2
cell treated with CDCA; B: HepG2 cell treated with GW4064; B: L02 cell treated with CDCA; D: L02 cell treated with GW4064. ⁄: compared with control, P < 0.05.
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that there is an interaction between FXR and ER1 (2904 to
2892 bp) in the human apoF promoter region, which is in consis-
tence with the Luciferase reporter assay result. (Fig. 3B)
3.4. CDCA treatment induces LTIP expression in C57/BL6 mice livers
We have shown that FXR up-regulates apoF expression in
HepG2 and L02 cells. To evaluate whether activation of FXR induce
apoF expression in vivo, we tested the liver apoF expression when
C57/BL6 mice treated with CDCA. Different concentrations (10 mg/
kg, 50 mg/kg) of CDCA resolved in plant oil were delivered by intra-
gastric administration to C57/BL6 male mice once a day for 1 week,
the apoF mRNA and protein levels were accessed by RT-PCR and
Western Blot respectively. The mRNA level of apoF in the liver in-
creased to about 2.5-fold (P < 0.05) (Fig. 4A and B), and the proteins
level of apoF in C57/BL6 mice liver increased to about 2.7 times
compared with control (P < 0.05) (Fig. 4C and D). These dataindicate that CDCA not only up-regulated apoF in liver cell cultures,
but also in the mice liver.
4. Discussion
The high level of plasma LDL and the low level of HDL are two
crucial factors in atherogenesis. HDL is responsible for the reverse
cholesterol transportation; it can take the cholesterol from the
peripheral tissue to the liver to metabolize, so it is believed that
HDL is capable of exerting positive effect on anti-atherosclerosis
[11]. Recent study shows that the transfer effect mediated by CETP
directly diminished the plasma HDL level, and increased the LDL
level, which could attenuate the reverse cholesterol transportation
[3]. So researchers propose that the inhibition of CETP could lead to
the anti-atherosclerosis effect [4]. By now, there are three artiﬁcial
CETP inhibitors that have been used in clinical experiments, some
of these experiments have been stopped because of the severe
hypertension side effect, however, the study of the CETP inhibitor
Fig. 3. Transcription activity of FXR on apoF is dependent on the FXRE in apoF
promoter. A: pGL3/ApoF(3289 to +22 bp)and pGL3/ApoF(1872 to +36 bp)were
transfected into the HepG2 cell with or without consistently active FXR expression
plasmid vp-FXR, after 24 h the cells were harvested and the ﬂuorescence was
measured by a ﬂuorescence photometric equipment. All values are normalized to
control with pGL3 basic plasmid transfected. B: HepG2 cell (106) were treated with
100 lmol/L CDCA for 24 h, the aliquot of lysate were precipitate with anti-FXR
antibody or IgG control, lysate without precipitation were loaded as Input. The
acquired DNA were assessed by PCR using primers targeting the promoter region
with predicted FXRE (2904 to 2892 bp) included.
Fig. 4. CDCA treatment induce apoF expression in mice liver C57/BL6 mice at
4 weeks age were treated with CDCA at concentrations of 10 mg/kg, 50 mg/kg or
vehicle control by intragastric administration once a day for a week, each group
includes six subjects and the representative results were showed. apoF expression
in mice liver were tested by RT-PCR and Western Blot. A, B: CDCA treatment
increase apoF mRNA level in liver; C, D: CDCA treatment increase apoF protein level
in liver. ⁄: compared with vehicle control, P < 0.05.
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inhibit CETP activity was separated from the plasma in 1982, and
has been named as apolipoprotein F (apoF), also known as Lipid
transfer inhibitor protein, LTIP [14]. It can inhibit the lipid transfer
by repressing CETP ability, the following studies shows that this ef-
fect is through the mechanism that the apoF competes with lipo-
proteins for the binding site of CETP [2,15]. Notably, it has been
found that the LTIP levels are inversely related to the triglyceride
levels [14,16].
In the regulation of lipid metabolism, FXR has played a crucial
role. The knowledge of the function of FXR focused on the partici-
pation of FXR in the bile acid metabolism, [17,18]. More and more
genes participated in lipid metabolism have been found to be reg-
ulated by FXR. In the following studies, FXR also played important
roles in the regulation of lipid metabolism. FXR could reduce the
TG synthesis by inhibiting the SREBP-1c [19] and PPARc [20], it
also can promote the activity of the LPL by up-regulating apoC-II
[9] and down-regulating apoC III [21]. LPL is a key enzyme which
catalyzes the triglycerides hydrolization; it can result in the degra-
dation of VLDL and CM, so as to reduce the plasma triglyceride con-
centration. Besides, apoE was also identiﬁed as a target gene of FXR
[22], the FXR and apoE double deﬁciency mice exhibited an aggra-
vation of atherogenesis versus apoE deﬁciency mice [23]. FXR tar-
get genes also have been involved in lipoprotein metabolism; it
may play a role in high density lipoprotein metabolism via the reg-
ulation of PLTP gene expression, a lipid transfer protein responsible
for phospholipid transfer from VLDL into HDL [24]. FXR activation
was also reported to induce the scavenger receptor B-I (SR-BI)
which is essential for HDL metabolism [10]. In all, FXR are believed
to have anti-atherosclerosis effects.
To study whether apoF is regulated by FXR, we observed if apoF
expression can be induced by FXR. Our data have shown that the
mRNA and protein levels of apoF increased signiﬁcantly in HepG2
and L02 cells treated with the native FXR agonist CDCA and the
artiﬁcial agonist GW4064, respectively.
Through bioinformatics analysis of the 3000 bp ﬂanking the 50
side of promoter region of LTIP, we have found a FXR binding siteER1 in its promoter. Luciferase reporter assay and ChIP assay indi-
cated that FXR up-regulated LTIP expression likely due to FXR di-
rectly bind to LTIP promoter by ER1 (2904 to 2892 bp).
To test whether FXR activation also increases apoF expression
in vivo, we delivered CDCA at 10 mg/kg and 50 mg/kg by intragas-
tric administration to C57/BL6 mice for one week respectively,
since apoF was mainly expressed in liver and then secreted into
plasma, we then sacriﬁced the mice and extract the total RNA
and protein of the mice liver. In accordance with the in vitro result,
apoF mRNA and protein levels were both elevated signiﬁcantly in
mice livers. These data conﬁrmed that FXR activation up -regulated
apoF expression in C57/BL6 mice liver.
Our ﬁnding suggested that apoF may be likely another target
gene of FXR, CETP inhibition is a promising therapy for lipid lowing
L. Li et al. / Biochemical and Biophysical Research Communications 441 (2013) 880–885 885and atherosclerosis protection, as a naturally existing protein and a
component of lipoprotein (mainly in HDL), which function to inhi-
bit CETP activity, apoF may serve as another option for CETP inhi-
bition and triglyceride lowering in plasma. More studies are
required to investigate the potential of FXR ligand-based therapy
in the treatment of dyslipidemia.
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